...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Pfizer

Another public offering??.....,,,if so and they get results from the 11 trials which some give us value,,,let it be an IPO for going to the NASDAQ,,,,!!,,,,minimum the TSX,,,,,,!!,,time ZENE's gamates dropped and if our science works to a fair degeree we get on an exchange and respect from the market!!,,but wait,,,,who is going to driect that??,,not our team,,they have no experience in this field!

Share
New Message
Please login to post a reply